Latest News
Opus Genetics, Inc.
- Opus Genetics receives FDA clearance for RDH12-LCA gene therapy By Investing.com
- Opus Genetics receives FDA clearance for RDH12-LCA gene therapy By Investing.com
- Opus Genetics at Chardan’s 10th annual healthcare conference: pipeline gains
- FDA Approves Opus Genetics’ Phentolamine Ophthalmic Solution 0.75% to Treat Presbyopia
- RTP’s Opus Genetics Presents Gene Therapy Data for Inherited Retinal Diseases at Retina in Rio 2026
- Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
- Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
- Citizens reiterates Opus Genetics stock rating on cohort progress
- Opus Genetics reports early trial results for gene therapies By Investing.com
- Opus Genetics, Inc. Presents Positive Clinical Data from OPGx-Best1 and OPGx-Lca5 Gene Therapy Programs At Retina in Rio 2026
- Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
- Opus Genetics Provides BEST1 Program Update
Headlines from the last 30 days, linking to the original publishers. See all market news →